


HEALTH SERVICES 2020



Lisata Therapeutics INC Rank 32 of 75





HEALTH SERVICES 2020



Lisata Therapeutics INC Rank 32 of 75

The relative strengths and weaknesses of Lisata Therapeutics INC are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Lisata Therapeutics INC compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 396% points. The greatest weakness of Lisata Therapeutics INC is the variable Net Income, reducing the Economic Capital Ratio by 87% points.

The company's Economic Capital Ratio, given in the ranking table, is 224%, being 121% points above the market average of 103%.

| Input Variable | Value in 1000 USD |
|---------------------------------------|----------------------|
| Assets, Current | 25,972 |
| Assets, Non-Current | 1,081 |
| Cost of Goods and Services Sold | 0 |
| Depreciation, Depletion, Amortization | 0 |
| General and Administrative Expense | 9,295 |
| Goodwill Impairment Loss | 0 |
| Intangible Assets | 0 |
| Labor Expense | 0 |
| Liabilities, Current | 5,976 |
| Long Term Liabilities | 624 |
| Operating Costs and Expenses | 0 |
| Other Assets | 0 |
| Other Compr. Net Income | 25 |
| Other Expenses | 0 |
| Other Liabilities | 0 |
| Other Net Income | 740 |
| Other Revenues | 0 |
| Property Plant and Equipment | 100 |
| Research And Development Expense | 10,797 |
| Selling and Marketing Expense | 0 |

| Output Variable | Value in 1000 USD |
|--------------------------|----------------------|
| Assets | 27,153 |
| Liabilities | 6,600 |
| Expenses | 20,092 |
| Revenues | 0 |
| Stockholders Equity | 20,553 |
| Net Income | -19,352 |
| Comprehensive Net Income | -19,327 |
| Economic Capital Ratio | 224% |

